Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122833
Filing Date
2024-11-07
Accepted
2024-11-07 08:22:41
Documents
68
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q amlx-20240930.htm   iXBRL 10-Q 2584366
2 EX-31.1 amlx-ex31_1.htm EX-31.1 16249
3 EX-31.2 amlx-ex31_2.htm EX-31.2 16241
4 EX-31.3 amlx-ex31_3.htm EX-31.3 16241
5 EX-32.1 amlx-ex32_1.htm EX-32.1 8602
6 EX-32.2 amlx-ex32_2.htm EX-32.2 8600
7 EX-32.3 amlx-ex32_3.htm EX-32.3 8599
  Complete submission text file 0000950170-24-122833.txt   8113349

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20240930.xsd EX-101.SCH 957474
70 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20240930_htm.xml XML 1257780
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 241433340
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)